Structure Therapeutics Inc at Topline Results from Aleniglipron ACCESS II Program Transcript
Good morning, and welcome to the Structure Therapeutics Conference Call. (Operator Instructions) Please be advised that this conference call is being recorded. I would now like to turn the call over to Corey Davis of LifeSci Advisors.
Thank you, Dan, and good morning, everyone. Earlier today, we issued a press release providing top line results from the ACCESS II clinical program for aleniglipron, our oral small molecule GLP-1 receptor agonist. A copy of this release and the presentation accompanying this call are available on the Investor Relations section of the Structure Therapeutics website.
I'd like to remind everyone that some of the statements we'll make on this call and information presented in the slide deck may include forward-looking statements, which you see here. These forward-looking statements involve a number of risks and uncertainties that could cause actual results to differ materially. Please refer to this slide as well as our SEC filings for a more detailed description of the
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
